Experimental vaccine aims to stop rare eye cancer from returning

NCT ID NCT01983748

First seen Feb 01, 2026 · Last updated May 13, 2026 · Updated 14 times

Summary

This phase 3 trial tests a personalized vaccine made from a patient's own immune cells and tumor RNA to prevent uveal melanoma from coming back after surgery. The study includes 200 people with a high-risk genetic type (monosomy 3) and no signs of spread. Half receive the vaccine over 2 years, the other half are simply watched. The goal is to see if the vaccine improves survival and keeps the cancer away.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dept. of Dermatology, University Hospital

    Erlangen, Bavaria, 90154, Germany

  • Städtisches Klinikum

    Dessau, 06847, Germany

  • University Hospital Department of Ophtalmology

    Erlangen, Bavaria, 91054, Germany

  • University Hospital Department of Ophtalmology

    Würzburg, Bavaria, 97080, Germany

  • University Hospital Department of Ophtalmology

    Essen, 45122, Germany

  • University Hospital Department of Ophtalmology

    Homburg/Saar, 66421, Germany

  • University Hospital Department of Ophtalmology

    Lübeck, 23538, Germany

  • University Hospital Department of Ophtalmology

    Tübingen, 72076, Germany

Conditions

Explore the condition pages connected to this study.